Get the Stockscreener App
16.83
1.41%
-0.24
After Hours:
16.83
Pieris Pharmaceuticals Inc stock is traded at $16.83, with a volume of 3,431.
It is down -1.41% in the last 24 hours and down -0.64% over the past month.
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store, and transport a wide spectrum of molecules. The Company's clinical pipeline consists of immuno-oncology, or IO, bispecifics in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Geographically, all the operations of the firm function through the region of the United States.
See More
Previous Close:
$17.07
Open:
$17.09
24h Volume:
3,431
Relative Volume:
0.17
Market Cap:
$22.22M
Revenue:
$40.93M
Net Income/Loss:
$-23.82M
P/E Ratio:
-45.49
EPS:
-0.37
Net Cash Flow:
$-37.87M
1W Performance:
+5.12%
1M Performance:
-0.64%
6M Performance:
+60.59%
1Y Performance:
+0.18%
1-Day Range:
$16.52
$17.09
1-Week Range:
$15.39
$17.09
52-Week Range:
$6.20
$22.32
Pieris Pharmaceuticals Inc Stock (PIRS) Company Profile
Name
Pieris Pharmaceuticals Inc
Sector
Industry
Phone
857-246-8998
Address
225 FRANKLIN STREET, BOSTON, MA
Compare PIRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PIRS
Pieris Pharmaceuticals Inc
|
16.83 | 22.22M | 40.93M | -23.82M | -37.87M | -0.37 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Pieris Pharmaceuticals Inc Stock (PIRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-30-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-19 | Initiated | Robert W. Baird | Outperform |
| Mar-19-18 | Initiated | Evercore ISI | Outperform |
| Mar-19-18 | Initiated | Jefferies | Buy |
| Jan-16-18 | Reiterated | H.C. Wainwright | Buy |
| May-30-17 | Initiated | Rodman & Renshaw | Buy |
| Aug-05-16 | Resumed | ROTH Capital | Buy |
| Aug-12-15 | Initiated | JMP Securities | Mkt Outperform |
| Jul-27-15 | Initiated | Oppenheimer | Outperform |
| Jul-22-15 | Initiated | ROTH Capital | Buy |
View All
Pieris Pharmaceuticals Inc Stock (PIRS) Latest News
PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc.PIRS - Marketscreener.com
Comparing Evelo Biosciences (NASDAQ:EVLO) and Pieris Pharmaceuticals (NASDAQ:PIRS) - Defense World
How To Trade (PIRS) - Stock Traders Daily
Lynx1 Capital Management LP Adjusts Stake in Pieris Pharmaceuticals Inc - GuruFocus.com
Pieris Pharmaceuticals: Q3 Earnings Snapshot - The Washington Post
Pieris Pharmaceuticals (NASDAQ:PIRS) Stock Rating Upgraded by StockNews.com - Defense World
(PIRS) Investment Analysis and Advice - Stock Traders Daily
Pieris Pharmaceuticals: Q2 Earnings Snapshot - Barchart
Pieris Pharmaceuticals director buys series F preferred stock for $1 By Investing.com - Investing.com South Africa
Pieris Pharmaceuticals director buys series F preferred stock for $1 - Investing.com
(PIRS) Technical Data - Stock Traders Daily
pieris pharmaceuticals, inc. Earnings dates - RTTNews
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer - The Manila Times
Learn to Evaluate (PIRS) using the Charts - Stock Traders Daily
(PIRS) Trading Signals - Stock Traders Daily
Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations - GlobeNewswire
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Sees Significant Decrease in Short Interest - Defense World
New Alzheimer’s Therapy Shows Remarkable Results in Animal Trials - SciTechDaily
How the (PIRS) price action is used to our Advantage - Stock Traders Daily
PIRS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pieris Pharmaceuticals, Inc. Is Fair to Shareholders - Business Wire
Wayne-based Palvella Therapeutics Poised to Go Public Later This Year - VISTA.Today
Pieris Pharmaceuticals Second Quarter 2024 Earnings: US$2.76 loss per share (vs US$3.63 profit in 2Q 2023) - Yahoo Finance
We're A Little Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate - Yahoo Finance
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc.PIRS - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of Shareholders - ForexTV.com
STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Mergers of PIRS, ENV, GVP - AccessWire
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. – PIRS - ForexTV.com
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Major Shareholder Adar1 Capital Management, Llc Purchases 3,000 Shares of Stock - Defense World
Adar1 capital management buys $92k worth of Pieris Pharmaceuticals stock - Investing.com
(PIRS) Long Term Investment Analysis - Stock Traders Daily
Pieris Pharmaceuticals (NASDAQ:PIRS) Stock Price Passes Above 50 Day Moving Average of $10.02 - Defense World
Global Chemotherapy Induced Anemia Drug Market 2024 Analysis by Top Key Players |SBI Pharmaceuticals Co. Ltd. - The NRI News
Public Equity Report: Palvella lands on NASDAQ via Pieris merger - BioCentury
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PIRS, EMLD, ACNB, GLXZ on Behalf of Shareholders - The Malaysian Reserve
General Mills, Inc. [GIS] gain 0.57% so far this year. What now? - The DBT News
Finansavisen - Finansavisen
Viking Therapeutics stock (VKTX) could hit all time high and here’s why - BP Journal
Pieris Pharmaceuticals ($PIRS) and Palvella Therapeutics Announce Exciting Merger - BP Journal
Is today’s surge in Dermata Therapeutics (DRMA) justified ? - BP Journal
Shareholder Alert: Ademi LLP investigates whether Pieris Pharmaceuticals, Inc. has obtained a Fair Price for its Public Shareholders - PR Newswire
Crude Oil Gains 1%; AT&T Shares Rise After Q2 Earnings - Benzinga
PIRS Stock on the Rise: A Promising Investment - The InvestChronicle
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session - Benzinga
Dow Tumbles 300 Points; Tesla Shares Plunge After Q2 Results - Benzinga
Why Is Pieris Pharmaceuticals (PIRS) Stock Up 77% Today? - InvestorPlace
Ivey Business School Opens the Market to celebrate Women in Asset Management Program - The Bubble
Pieris Pharmaceuticals Inc Stock (PIRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pieris Pharmaceuticals Inc Stock (PIRS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 10% Owner |
Aug 12 '24 |
Buy |
15.88 |
3,000 |
47,647 |
129,574 |
| ADAR1 Capital Management, LLC | 10% Owner |
Aug 09 '24 |
Buy |
14.89 |
3,000 |
44,679 |
127,331 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):